Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α

Pedersen,Astrid  M.; Thrane,Susan; Lykkesfeldt,Anne  E.; Yde,Christina  W.

doi:10.3892/ijo.2014.2619

Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α

Authors:
- Astrid M. Pedersen
- Susan Thrane
- Anne E. Lykkesfeldt
- Christina W. Yde
View Affiliations

Affiliations: Breast Cancer Group, Cell Death and Metabolism, Danish Cancer Society Research Center, 2100 Copenhagen Ø, Denmark
Published online on: August 22, 2014 https://doi.org/10.3892/ijo.2014.2619
Pages: 2167-2175

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tamoxifen‑resistant breast cancer is a major clinical problem and new treatment strategies are highly warranted. In this study, the multitargeting kinase inhibitors sorafenib and nilotinib were investigated as potential new treatment options for tamoxifen‑resistant breast cancer. The two compounds inhibited cell growth, reduced expression of total estrogen receptor α (ER), Ser118-phosphorylated ER, FOXA1 and AIB1 and resensitized tamoxifen‑resistant cells to tamoxifen. The ER downmodulator fulvestrant exerted strong growth inhibition of tamoxifen‑resistant cells and addition of sorafenib and nilotinib could not further suppress growth, showing that sorafenib and nilotinib exerted growth inhibition via ER. In support of this, estradiol prevented sorafenib and nilotinib mediated growth inhibition. These results demonstrate that sorafenib and nilotinib act via ER and ER-associated proteins, indicating that these kinase inhibitors in combination with tamoxifen may be potential new treatments for tamoxifen‑resistant breast cancer.

View Figures

View References

1	Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar
2	Dutertre M and Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 295:431–437. 2000.PubMed/NCBI
3	Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS and Yde CW: Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 139:71–80. 2013. View Article : Google Scholar : PubMed/NCBI
4	Lavinsky RM, Jepsen K, Heinzel T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA. 95:2920–2925. 1998. View Article : Google Scholar : PubMed/NCBI
5	Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D and Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 43:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
6	Xu J and Li Q: Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol. 17:1681–1692. 2003. View Article : Google Scholar : PubMed/NCBI
7	Font de Mora J and Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 20:5041–5047. 2000.PubMed/NCBI
8	Bunone G, Briand PA, Miksicek RJ and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174–2183. 1996.PubMed/NCBI
9	Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1491–1494. 1995. View Article : Google Scholar : PubMed/NCBI
10	Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 276:9817–9824. 2001. View Article : Google Scholar : PubMed/NCBI
11	Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
12	Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
13	Plaza-Menacho I, Morandi A, Robertson D, et al: Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene. 29:4648–4657. 2010. View Article : Google Scholar
14	Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
15	Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
16	Luu T, Frankel P, Chung C, et al: Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer. Clin Breast Cancer. 14:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
17	Baselga J, Costa F, Gomez H, et al: A phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 14:2282013. View Article : Google Scholar
18	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
19	Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A and Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 94:1765–1769. 2006. View Article : Google Scholar : PubMed/NCBI
20	O’Hare T, Walters DK, Deininger MW and Druker BJ: AMN107: tightening the grip of imatinib. Cancer Cell. 7:117–119. 2005.PubMed/NCBI
21	Piccaluga PP, Paolini S, Bertuzzi C, De Leo A and Rosti G: First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. J Blood Med. 3:151–156. 2012. View Article : Google Scholar : PubMed/NCBI
22	Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M and Martin LA: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res. 14:R782012. View Article : Google Scholar
23	Briand P and Lykkesfeldt AE: Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res. 44:1114–1119. 1984.PubMed/NCBI
24	Lykkesfeldt AE, Madsen MW and Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAM^R-1. Cancer Res. 54:1587–1595. 1994.PubMed/NCBI
25	Lundholt BK, Briand P and Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 67:199–214. 2001. View Article : Google Scholar
26	Larsen MS, Yde CW, Christensen IJ and Lykkesfeldt AE: Carboplatin treatment of antiestrogen-resistant breast cancer cells. Int J Oncol. 41:1863–1870. 2012.
27	Arnold SF, Obourn JD, Jaffe H and Notides AC: Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. J Steroid Biochem Mol Biol. 55:163–172. 1995. View Article : Google Scholar : PubMed/NCBI
28	De Leeuw R, Neefjes J and Michalides R: A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011:2324352011.PubMed/NCBI
29	Chen D, Riedl T, Washbrook E, et al: Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell. 6:127–137. 2000. View Article : Google Scholar : PubMed/NCBI
30	Wijayaratne AL and McDonnell DP: The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem. 276:35684–35692. 2001. View Article : Google Scholar
31	Osborne CK, Wakeling A and Nicholson RI: Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 90(Suppl 1): S2–S6. 2004. View Article : Google Scholar : PubMed/NCBI
32	Kroemer G and Jaattela M: Lysosomes and autophagy in cell death control. Nat Rev Cancer. 5:886–897. 2005. View Article : Google Scholar : PubMed/NCBI
33	Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI
34	Hodges LC, Cook JD, Lobenhofer EK, et al: Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res. 1:300–311. 2003.PubMed/NCBI
35	Vendrell JA, Bieche I, Desmetz C, et al: Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer. 12:75–92. 2005. View Article : Google Scholar : PubMed/NCBI
36	Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 95:353–361. 2003. View Article : Google Scholar : PubMed/NCBI
37	Su Q, Hu S, Gao H, et al: Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology. 75:159–168. 2008. View Article : Google Scholar : PubMed/NCBI
38	Smith CL, Nawaz Z and O’Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 11:657–666. 1997. View Article : Google Scholar : PubMed/NCBI
39	Reiter R, Oh AS, Wellstein A and Riegel AT: Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene. 23:403–409. 2004. View Article : Google Scholar : PubMed/NCBI
40	Rahmani M, Davis EM, Crabtree TR, et al: The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 27:5499–5513. 2007. View Article : Google Scholar : PubMed/NCBI
41	Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
42	Shaker ME, Ghani A, Shiha GE, Ibrahim TM and Mehal WZ: Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochim Biophys Acta. 1833:1992–2003. 2013. View Article : Google Scholar : PubMed/NCBI